FinscoFinsco

Amphastar Pharmaceuticals (US.AMPH)

资本配置审计 · 期间： 2011 – 2026

$打开交互终端运行 `audit` 并探索所有维度。→

核心指标

US.AMPH · 同比： 2026 H1 vs 2025 H1

指标数值同比
FCF Conversion81.7%↑
ROE4.8%↓
Cash Conversion269.7%↑
D/E Ratio0.90→
Gross Margin46.1%↓
US.AMPH (Amphastar Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    81.7%    ↑
ROE                4.8%    ↓
Cash Conversion  269.7%    ↑
D/E Ratio          0.90    →
Gross Margin      46.1%    ↓
核心指标
US.AMPH (Amphastar Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 81.7% ↑
ROE 4.8% ↓
Cash Conversion 269.7% ↑
D/E Ratio 0.90 →
Gross Margin 46.1% ↓

审计维度

资本流向回报率指标盈利质量负债纪律护城河评估

免费公司

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies